kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human IL-1 RAcP / IL-1 R3 Protein, Fc Tag, 5 x 200 µg  

Recombinant Human IL-1 RAcP / IL-1 R3 Protein, Fc Tag, 5 x 200 µg

Recombinant Human IL1RAP /IL-1RAcP /IL1R3 Protein, Ser 21 - Glu 359,  expressed in human 293 cells (HEK293), Fc tag

Recombinant Human protein, IL1RAP, IL-1RAcP, C3orf13, IL1R3

More details


Availability: within 7 days

1 078,00 €

Interleukin-1 receptor accessory protein (IL1RAP or IL-1RAcP) is also known as Interleukin-1 receptor 3 (IL-1R-3 or IL-1R3), C3orf13, which belongs to the interleukin-1 receptor family. IL1RAP contains three Ig-like C2-type (immunoglobulin-like) domains and one TIR domain. IL1RAP is detected in liver, skin, placenta, thymus and lung. IL-1R3 / IL1RAP is coreceptor with IL1R1, associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways.

Recombinant Human IL-1 RAcP, Fc Tag (ILP-H5256) is expressed from human 293 cells (HEK293). It contains AA Ser 21 - Glu 359 (Accession # Q9NPH3).
Predicted N-terminus: Ser 21

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 65.7 kDa. The protein migrates as 75-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg of the rh IL1RAP / IL-1RAcP / IL1R3 Fc Chimera by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).


(1) Huang J., et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94:12829-12832.
(2) Jensen L.E., et al., 2000, J. Immunol. 164:5277-5286.
(3) Smith D.E., et al., 2003, Immunity 18:87-96.